Global Interstitial Lung Disease Treatment Market Overview

Global Interstitial Lung Disease Treatment Market was valued at USD 1.1 Billion in 2023 and is expected to reach USD 1.70 Billion by the year 2032, at a CAGR of 4.97%.

Interstitial lung disease (ILD) encompasses a diverse range of respiratory disorders characterized by inflammation and progressive scarring (fibrosis) of lung tissue. This scarring leads to stiffness in the lungs, impairing their ability to exchange gases effectively and resulting in inadequate oxygen supply to the bloodstream. Symptoms of ILD typically include shortness of breath, dry coughing, fatigue, and weight loss, which can worsen over time, leading to significant complications for affected individuals.

• The treatment market for ILD is evolving in response to the growing prevalence of these diseases, driven by factors such as environmental pollution, genetic predisposition, and the impact of medical treatments like chemotherapy and radiation. As the awareness of ILD increases and research advances, the market is expanding to accommodate a variety of therapeutic options aimed at managing symptoms and slowing disease progression.
• Current treatment strategies for ILD focus on alleviating symptoms and enhancing the quality of life for patients. These include corticosteroids to reduce inflammation, antifibrotic medications like pirfenidone and nintedanib to slow down fibrosis, and supplemental oxygen therapy to improve oxygenation. Additionally, lung rehabilitation programs can help patients regain physical function and manage daily activities more effectively.
• Innovations in drug development and increased research investment are expected to stimulate the ILD treatment market further. The demand for personalized treatment plans and targeted therapies is on the rise, driven by a better understanding of the underlying mechanisms of different ILD types. As a result, the ILD treatment market is projected to experience significant growth in the coming years, fueled by advancements in diagnostic techniques and the introduction of novel therapeutic agents, ultimately leading to improved patient outcomes and enhanced quality of life.

Market Dynamics and Key Factors of Interstitial Lung Disease Treatment:

Drivers:

Interstitial lung diseases are caused by more than 200 factors. Individuals suffering from autoimmune disorders such as lupus, scleroderma, polymyositis/dermatomyositis, and rheumatoid arthritis may also develop ILDs. In autoimmune disorders, an individual’s immune system attacks the lungs that resulting in scarring of lungs, thus impairing the functioning of the lungs. Moreover, people working in the coal and asbestos field inhale thousands of small particulate substances. People working in these fields for a longer duration have a high chance of developing ILDs in their lifetime. In addition, people who breathe harmful gases such as tobacco smoke or hairdressing chemicals may also develop ILDs.

In genetic ILD, the disease is inherited from parents to their offspring and these conditions mostly include neurofibromatosis and Gaucher disease. The growing prevalence of autoimmune disorders and the rise in the smoking population are the two essential factors expected to stimulate the expansion of the interstitial lung disease treatment market in the forecast period. People are becoming more aware of the various treatment methods that can help resolve other complications associated with ILDs. Individuals over 50 years of age are more susceptible to ILDs as compared to other age groups. Over the past decade, there has been a significant rise in the geriatric population thus, the demand for treatment of ILD is expected to exponentially grow in the forecasted period. The rise in the adoption of interstitial lung disease treatment methods coupled with the growing R&D activities is expected to support the expansion of the market in the projected period.

Restraints:

Unawareness about the benefits of interstitial lung disease treatment and the negligence shown by individuals towards screening methods to diagnose ILDs are the essential factors that are hindering the expansion of the market in the forecast period. Furthermore, people taking oral medications may suffer from certain allergic reactions which can exaggerate the disease condition. Cyclophosphamide a drug administered in the treatment of ILDs can cause damage to the bladder, immunosuppression, and alopecia thus, complications associated with the treatment methods may hamper the development of the market in the projected timeframe.

Opportunities:

Air pollution has been a matter of concern for all countries across the globe. Various harmful substances are released into the atmosphere due to the burning of coal, tobacco, and other materials which results in the development of ILDs in people who have a weak immune system. According to Scientific American, 4.5% of the total world population is affected by autoimmune disorders. As autoimmune individuals are more susceptible to ILDs it is expected that it will create a profitable opportunity for the market players to discover novel drugs that can treat both the autoimmune disorder and ILD. Furthermore, the majority of the population suffering from ILDs lives in developing regions. Manufacturers can target these regions to increase their revenue and launch new products in these markets to meet the needs of patients in this region, and make treatment of ILDs affordable. Supportive government policies and voluntary participation of candidates for trials of novel drugs are the essential factors that are expected to generate a lucrative opportunity for the market players.

Market Segmentation For ILD Treatment

Depending on the diagnosis, the CT scan segment is anticipated to have the highest share of the ILD treatment market throughout the forecast period. CT scanners utilize a computer to combine X-ray images that are taken from different angles to produce a cross-sectional image of internal structures. A high-resolution CT (HRCT) scan can help in evaluating the extent of the lung damage caused by ILDs. In addition, a CT scan can show the detailed spread of the fibrosis, which can assist the healthcare provider in narrowing down the diagnosis and in guiding appropriate treatment. The growing popularity of HRCT among healthcare providers to detect the early signs of ILDs is expected to support the development of this segment in the forecast period.

Depending on the disease type, the sarcoidosis form of the disease is expected to be more prevalent in the projected period. Sarcoidosis is an inflammatory disease that causes the immune system to overreact, resulting in the formation of inflamed tissue called granulomas in the lungs and lymph nodes. According to the Sarcoidosis Research Foundation, about 200,000 cases are diagnosed annually in the United States. Individuals of any age group are susceptible to sarcoidosis but people of African and Scandinavian descent are more at risk.

Depending on the treatment, the corticosteroids segment is predicted to lead the ILDs market in the analysis period. Corticosteroids are often the most common first medication administered to treat many forms of ILDs. Corticosteroids are widely administered along with other drugs that are mainly immunosuppressants. Depending on the cause of the ILDs, this combination can stabilize or even slow down the progression of the disease. Corticosteroids reduce inflammation in the lung thus, making it easier for the patient to breathe thus, consolidating the expansion of the segment in the projected period.

Depending on the route of administration, the oral segment is expected to lead the ILDs treatment market throughout the projected period. Oral medications are most proffered by patients as these can be easily self-administered. Oral drugs are simple to consume, convenient, and non-invasive. Additionally, oral medications are less costly as compared to other forms of medications, thus supporting the growth of the segment. 

Players Covered in Interstitial Lung Disease Treatment market are :

• F. Hoffman - La Roche Ltd (Switzerland)
• Merck Sharp & Dohme Corp. (US)
• Boehringer Ingelheim International GmbH (Germany)
• J.B. Chemicals & Pharmaceutical (India)
• Galecto Inc (Denmark)
• Cipla Ltd (India)
• Glenmark Pharma (India)
• Gilead Sciences Inc (US)
• Bristol-Myers Squibb Company (US)
• FibroGen Inc (US)
• Liminal Biosciences (Canada) and others major players.

Regional Analysis of Interstitial Lung Disease Treatment Market:

The North American region is anticipated to dominate the ILD treatment market during the forecast period attributed to the presence of prominent manufacturers in this region. Idiopathic pulmonary fibrosis (IPF) is the most common form of ILD. About 15-20 people per 100,000 people are suffering from IPF worldwide. According to Medline Plus, 100,000 Americans are affected by ILD and around 30,000 to 40,000 cases are diagnosed every year in the United States. Moreover, 39,000 American lives succumbed to Asbestosis in the USA every year. Thus, the increasing number of individuals suffering from ILD is supporting the development of the market in this region.

The European region is expected to have the second-highest share of the ILD treatment market in the projected period. The growing air pollution and the rise in the number of smokers in this region are expected to fuel the growth of the ILD treatment market. According to Eurostat, 18.4% of the EU population aged over 15 years smoke tobacco daily. The smoker’s population is high in Bulgaria (28.7%), Greece (23.6%), Latvia (22.1%), Germany (21.9%), and Croatia (21.8%). Smoking tobacco is one of the main factors that promote the development of ILD in individuals thus, the gradual rise in the smoking population will elevate the number of ILD patients and hence will aid in the expansion of the market.

The ILD treatment market in the Asia-Pacific region is anticipated to develop at the highest CAGR during the projected period attributed to the legal as well as illegal mining of asbestos. Since the early 1970s more than 50 countries put a ban on mining activities of asbestos. Even though the popularity of asbestos in developing nations is growing over the years attributed to the aggressive industry campaigns. Additionally, asbestos is affordable as well the mass production of building material is high in demand in this region. Thus, the growing usage of asbestos is stimulating the rise in the number of patients suffering from ILD. According to the National Health Portal of India, approximately 107,000 people die each year due to asbestos-related diseases thus, driving the growth of the market.

Recent Industry Developments in Interstitial Lung Disease Treatment Market:

• In April 2024, BioInvent International AB (Nasdaq Stockholm: BINV) announced a clinical trial collaboration and supply agreement with MSD International Business GmbH, a subsidiary of Merck & Co., Inc. This collaboration focused on a Phase 1/2a study evaluating BioInvent's monoclonal antibody, BI-1910, in combination with KEYTRUDA® (pembrolizumab) for cancer immunotherapy. The agreement aimed to explore the potential of this innovative combination to enhance immune modulation in cancer treatment. BioInvent expressed excitement about partnering with Merck to advance this important clinical trial and contribute to the development of novel therapies for cancer patients.

• In February 2023, Roche announced the expansion of its collaboration with Janssen Biotech Inc. to enhance personalized healthcare through the development of companion diagnostics for targeted therapies. This strengthened partnership aimed to accelerate research and innovation in identifying patient populations most likely to benefit from specific treatments. The collaboration underscored Roche's commitment to advancing precision medicine by integrating diagnostic insights with therapeutic advancements. Both companies expressed their enthusiasm for the potential impact of this initiative on improving patient outcomes and transforming the treatment landscape in various disease areas. The partnership represents a significant step forward in personalized healthcare solutions.